Trial Profile
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, HBeAg+, Chronic Hepatitis B Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs INO 1800 (Primary) ; INO 9112 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals; Roche
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Mar 2018 According to an Inovio Pharmaceuticals media release, company plans to report additional data from this trial at upcoming scientific conferences and in a publication.
- 14 Mar 2018 Interim results presented in the Inovio Pharmaceuticals media release.